IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer
This study is currently recruiting participants.
Verified March 2016 by Thorsten Fuereder, Medical University of Vienna
Sponsor:
Medical University of Vienna
Information provided by (Responsible Party):
Thorsten Fuereder, Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT02718820
First received: March 15, 2016
Last updated: March 23, 2016
Last verified: March 2016
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | August 2018 |
| Estimated Primary Completion Date: | January 2018 (Final data collection date for primary outcome measure) |